vadadustat

Following Akebia Therapeutics Inc's (NASDAQ: AKBA) announcement of an expanded agreement with Otsuka (OTC: OTSKY) to develop and commercialize Vadadustat in Europe, China and Other Territories, HC Wainwright said in a note that the European partnership provides strong economics, removing any...

Analysts at JMP Securities believe Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that develops therapeutics based on hypoxia-inducible factor (HIF) biology, could deliver investors a triple-digit percentage return. JMP's Michael King maintains an Outperform rating on Akebia's...

On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: JNJ) to access hundreds of hypoxia inducible factor (HIF)-targeted compounds. This access includes a coveted preclinical candidate for inflammatory bowel disease (...